Nath Bio-Genes Ltd. has made a regulatory disclosure pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The company received a communication dated 05th August 2026 from the Securities and Exchange Board of India (SEBI). This communication informed the company that SEBI has appointed CNK & Associates LLP as the Forensic Auditor to conduct a forensic audit in respect of the company.
The forensic audit will examine the books of account and records of the company for the financial years 2020-21 to 2025-26. The audit will be conducted with reference to specific matters specified by SEBI in its communication, though these specific matters are not detailed in this disclosure.
The company states it is extending and shall continue to extend its full cooperation to the Forensic Auditor. It pledges to provide all information, records, and assistance as may be required for the completion of the audit.
Regarding financial impact, the disclosure explicitly states that at this stage, the company is not in a position to comment further pending completion of the forensic audit. Therefore, the financial impact is not quantified in this disclosure.
The company concludes by affirming its commitment to maintaining the highest standards of corporate governance, transparency, and regulatory compliance.